Oct 5 – 7, 2026
Hotel Berlin, Berlin
Europe/Berlin timezone
>> Safe the date for the next symposium: September 29 – October 1, 2027 <<

Hepatitis E virus in shrews – a novel zoonotic risk?

Oct 5, 2026, 7:04 PM
1m
Area C

Area C

Poster presentation Novel and Emerging Pathogens Snacks & Poster Viewing I

Speaker

Dr Calvin Mehl (Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Germany)

Description

Paslahepevirus balayani (hepatitis E virus, HEV) is the most relevant human-pathogenic hepevirus, but zoonotic infections with ratHEV (species Rocahepevirus ratti) have been reported recently. A novel hepevirus, provisionally termed shrewHEV, was identified in Crocidura russula (greater white-toothed shrews, GWTS) that is phylogenetically more closely related to HEV than ratHEV. We investigated its prevalence in Germany and its infectivity in various cell lines.
222 GWTS collected in Germany between 2002 and 2022 were screened for shrewHEV RNA by RT-qPCR. ShrewHEV RNA sequences were determined and phylogenetically analysed. Liver homogenates of ten positive shrews were inoculated onto shrew-derived fibroblast-like cells and three HEV- and ratHEV-permissive human liver cell lines. Cells and supernatants were characterized by immunofluorescence assay, sequencing and density gradient centrifugation. Finally, we assessed the antiviral activity of ribavirin (RBV) and sofosbuvir (SOF) against shrewHEV.
ShrewHEV RNA was detected in 16/222 GWTS. Five of 10 liver-derived strains replicated in human liver cell lines, but none in shrew cells. Density gradient centrifugation demonstrated quasi-enveloped particles. Both RBV and SOF showed antiviral activity against shrewHEV in vitro. ShrewHEV was detected in 7.2% of GWTS across its distribution range. The virus replicated efficiently in human-derived liver cells indicating the necessity of further studies on its zoonotic potential.

Keywords

Shrews, hepatitis E, isolation, zoonotic

Registration ID OHS26-0079
Professional Status of the Speaker Postdoc
Junior Scientist Status No, I am not a Junior Scientist.

Authors

Dr Calvin Mehl (Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Germany) Dr Mathias Schemmerer (University Medical Center Regensburg, National Consultant Laboratory for HAV and HEV, Germany)

Co-authors

Dr Viola Haring (Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Germany) Dr Alexander Falkenhagen (German Federal Institute for Risk Assessment, Department of Biological Safety, Germany) Ms Anna Brueck (Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Germany) Dr Matthias Lenk (Friedrich-Loeffler-Institut, Department of Experimental Animal Facilities and Biorisk Management, Germany) Monika Erl (University Medical Center Regensburg, National Consultant Laboratory for HAV and HEV, Germany) Prof. Juergen Wenzel (University Medical Center Regensburg, National Consultant Laboratory for HAV and HEV, Germany) Dr Florian Pfaff (Friedrich-Loeffler-Institut, Institute of Diagnostic Virology, Germany) Prof. Reimar Johne (German Federal Institute for Risk Assessment, Department of Biological Safety, Germany) Prof. Rainer G. Ulrich (Friedrich-Loeffler-Institut, Institute of Novel and Emerging Infectious Diseases, Germany)

Presentation materials

There are no materials yet.

External references

Peer reviewing

Paper